These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 26282478)

  • 1. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?
    Groenke L; Disse B
    Lancet Respir Med; 2015 Aug; 3(8):e26. PubMed ID: 26282478
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts.
    Jaroenpuntaruk V; Pongdee T
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1394-1396. PubMed ID: 38724168
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord I
    Lancet Respir Med; 2015 Aug; 3(8):e27. PubMed ID: 26282479
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.
    O'Byrne PM; D'Urzo T; Beck E; Fležar M; Gahlemann M; Hart L; Blahova Z; Toorawa R; Beeh KM
    Respir Res; 2015 Aug; 16(1):97. PubMed ID: 26283085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
    Singh D; Worsley S; Zhu CQ; Hardaker L; Church A
    BMC Pulm Med; 2015 Aug; 15():91. PubMed ID: 26286141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
    Iqbal A; Barnes NC; Brooks J
    Clin Drug Investig; 2015 Oct; 35(10):685-8. PubMed ID: 26329916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort.
    Cosio BG; Soriano JB; López-Campos JL; Calle-Rubio M; Soler-Cataluna JJ; de-Torres JP; Marín JM; Martínez-Gonzalez C; de Lucas P; Mir I; Peces-Barba G; Feu-Collado N; Solanes I; Alfageme I; Casanova C;
    Chest; 2016 Jan; 149(1):45-52. PubMed ID: 26291753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.
    Pavord ID; Lettis S; Locantore N; Pascoe S; Jones PW; Wedzicha JA; Barnes NC
    Thorax; 2016 Feb; 71(2):118-25. PubMed ID: 26585525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum eosinophils as a COPD biomarker: ready for prime time?
    Iyer AS; Dransfield MT
    Lancet Respir Med; 2016 May; 4(5):341-3. PubMed ID: 27066738
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
    Barnes NC; Sharma R; Lettis S; Calverley PM
    Eur Respir J; 2016 May; 47(5):1374-82. PubMed ID: 26917606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.
    Bakerly ND; Woodcock A; New JP; Gibson JM; Wu W; Leather D; Vestbo J
    Respir Res; 2015 Sep; 16(1):101. PubMed ID: 26337978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Ora J; Matera MG
    Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
    J Asthma; 2015; 52(10):1073-83. PubMed ID: 26291137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.
    Roche N; Chapman KR; Vogelmeier CF; Herth FJF; Thach C; Fogel R; Olsson P; Patalano F; Banerji D; Wedzicha JA
    Am J Respir Crit Care Med; 2017 May; 195(9):1189-1197. PubMed ID: 28278391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions.
    Couillard S; Larivée P; Courteau J; Vanasse A
    Chest; 2017 Feb; 151(2):366-373. PubMed ID: 27746201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
    Pavord ID; Lettis S; Anzueto A; Barnes N
    Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.
    Vedel-Krogh S; Nielsen SF; Lange P; Vestbo J; Nordestgaard BG
    Am J Respir Crit Care Med; 2016 May; 193(9):965-74. PubMed ID: 26641631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J; Zhong N; Newlands A; Church A; Goh AH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network analysis: a way forward for understanding COPD multimorbidity.
    Faner R; Agustí A
    Eur Respir J; 2015 Sep; 46(3):591-2. PubMed ID: 26324686
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.
    Anderson DE; Kew KM; Boyter AC
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011397. PubMed ID: 26301488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.